Paying $3B: GSK tops US criminal, civil settlements for off-label, other schemes
This article was originally published in Scrip
Beating the competition is the name of the game in business. But GlaxoSmithKline's $3 billion settlement with the US government to resolve criminal and civil charges – topping rival New York-based Pfizer's $2.3 billion deal – is not likely what the London drug giant had in mind for outdoing its competitors.
You may also be interested in...
GSK Revamps Sales Reps Incentives To Be Competitive In Cancer
Seven years after a major shift in how the company compensated its sales force, the UK major has done a U-turn and is adapting pay packages for some specialty care reps.
Moderna's Valera Takes mRNA Approach To Combat Zika
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan's Price Reform Pledge: Will Others Follow?
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.